Why the study?
The ketogenesis enzyme Hmgcs2 is upregulated in atrial and ventricular tissues of T2DM mice alongside increased cardiac and circulating beta-hydroxybutyrate, but whether enhanced Hmgcs2 is related to AF via ketogenesis-dependent or independent mechanisms remained unclear.
Does cardiomyocyte-specific Hmgcs2 knockdown reduce atrial fibrillation inducibility and improve cardiac metabolism in a mouse model of type 2 diabetes?
Does cardiomyocyte-specific Hmgcs2 knockdown reduce atrial fibrillation inducibility and improve cardiac metabolism in a mouse model of type 2 diabetes?
Identifies myocardial Hmgcs2-mediated ketogenesis as a driver of diabetic atrial fibrillation and diastolic dysfunction, positioning cardiac Hmgcs2 as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Challenges traditional view of hepatic ketone origin in T2DM; leaves open whether cardiac ketogenesis promotes AF.
BACKGROUND: Type 2 diabetes (T2DM) increases the risk of atrial fibrillation (AF). Elevated circulating ketone bodies (β-hydroxybutyrate [β-OHB]) in T2DM are considered hepatic in origin and benefit the heart via energy provision. Although we found ketogenesis enzyme Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) upregulated in both atrial and ventricular tissues of T2DM mice, alongside increased cardiac and circulating β-OHB. Whether enhanced Hmgcs2 is related to AF, ketogenesis-dependent or independent, remained unclear. METHODS: T2DM mice were induced by high-fat diet and followed by streptozocin injection. Cardiac-specific Hmgcs2 overexpression and cardiomyocyte-specific Hmgcs2 knockout were conducted in T2DM mice. Cardiac function and left atrial diameter were evaluated using echocardiography, and cardiac electrophysiology was examined through electrical mapping. Programmed electrical stimulation was delivered to induce AF. Blood metabolomics from the coronary sinus and left atria of patients with or without T2DM were analyzed. RESULTS: The heart functioned as a primary ketogenic organ in T2DM mice via upregulating Hmgcs2, surpassing the liver. Hmgcs2-mediated shunting of fatty acid-derived acetyl-CoA into ketogenesis depleted myocardial energy reserves, exacerbated oxidative stress, and caused mitochondrial injury, ultimately increasing AF inducibility and diastolic dysfunction. In addition, cardiac-derived β-hydroxybutyrate released into circulation prolonged action potential duration in atrial cardiomyocytes. Mechanistically, Hmgcs2-mediated cytosolic β-hydroxybutyrylation targeted Oxct1 (3-oxoacid CoA-transferase 1) for degradation, blocking cardiac ketolysis. Blood metabolomics from the coronary sinus and left atria confirmed active cardiac ketogenesis in patients with T2DM and heart-derived ketone release into systemic circulation. Venous plasma β-OHB levels positively correlated with atrial low-voltage burden and postablation AF recurrence. Cardiomyocyte-specific Hmgcs2 knockdown improved cardiac utilization of fatty acids, β-OHB, and glucose in T2DM mice by suppressing cardiac ketogenesis; this intervention, with reduced circulating β-OHB, attenuated diabetes-associated AF. CONCLUSIONS: Cardiac Hmgcs2 represented a novel therapeutic target for diabetic AF and heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: